January 19, 2022 Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings 典晶生物宣布从 Retinagenix Holdings 公司收购其 Zuretinol 资产
January 17, 2022 Eluminex Biosciences Successfully Completes Its First Pre-IND Meeting with the United States Food and Drug Administration for a Multivalent Fc Fusion Protein (EB-101) for the Treatment of Neovascular Age-related Macular Degeneration 典晶生物成功地与美国FDA就一种治疗新生血管年龄相关性黄斑病变的项目召开Pre-IND 会议
January 5, 2022 Eluminex Further Expands Leadership Team and Receives New Awards 典晶生物首席执行官张金忠博士荣膺两项人才称号并宣布进一步扩大公司高级管理层
December 30, 2021 Eluminex CEO Was Invited as a Guest Speaker at the DeviceChina 2021 and a Panelist at the China Healthcare Summit 典晶生物首席执行官张金忠博士受邀出席 DeviceChina 2021 和 China Healthcare Summit
October 13, 2021 Eluminex Biosciences Announces the Grand Opening of New Global Headquarters and Research and Development Center in Suzhou 典晶生物开业典礼成功举办
July 20, 2021 Eluminex Biosciences Expands Leadership Team and Receives Award 典晶生物宣布扩大高级管理层和荣获中国潜在独角兽企业称号
July 19, 2021 Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform 典晶生物获得珐博进生物合成角膜技术及重组III型人胶原蛋白平台独占许可权
November 27, 2020 Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing Portfolio | 专注眼科创新药研发的典晶生物完成五千万美元A轮融资 (qq.com)
